NASDAQ:EXEL
Exelixis Stock News
$20.91
-0.320 (-1.51%)
At Close: May 17, 2024
Exelixis (EXEL) Received its Third Buy in a Row - Markets
03:15pm, Monday, 19'th Oct 2020
After Oppenheimer and Piper Sandler gave Exelixis (NASDAQ: EXEL) a Buy rating last month, the company received another Buy, this
Analysts Expect Exelixis, Inc. (NASDAQ:EXEL) Will Post Earnings of $0.05 Per Share
07:06am, Monday, 19'th Oct 2020
Wall Street analysts predict that Exelixis, Inc. (NASDAQ:EXEL) will post earnings per share of $0.05 for the current quarter, Zacks reports. Five analysts have provided estimates for Exelixis’ earni
US FDA Accepts for Priority Review Applications for OPDIVO® in Combination with CABOMETYX® in Advanced Renal Cell Carcinoma
2 Great Stocks to Buy With Just $100 | The Motley Fool
01:12pm, Tuesday, 13'th Oct 2020
$100 can go a long way in the stock market -- if you play your cards right.
3 Safe Stocks for a Coming Market Crash | The Motley Fool
11:49am, Tuesday, 13'th Oct 2020
Look for proven resilience and growth prospects on the horizon.
Pfizer Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma (NYSE:PFE)
08:01am, Sunday, 11'th Oct 2020
Pfizer reports encouraging results for growth hormone deficiency trial. Dexcom collaborates with Lilly for diabetes management program.
Oct 09, 2020 (The Expresswire) --
Global Oncology Apoptosis Modulators Market Research Report offers an in-depth analysis of the market size (revenue),...
Oct 09, 2020 (The Expresswire) --
Global and United States Renal Cell Cacinoma Drugs Market 2020 industry research report gives Advancement strategies and...
Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent...
Exelixis, Inc. (NASDAQ: EXEL) today announced new data that support the ongoing clinical development of XL092, the company’s next-generation oral tyrosine...
Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has pote
These Are the 3 Biggest Bargains in Biotech | The Motley Fool
11:21am, Wednesday, 07'th Oct 2020
Drug developers don't get much cheaper than this.
Why Exelixis Jumped 10% in September | The Motley Fool
06:23pm, Tuesday, 06'th Oct 2020
The biotech was the beneficiary of a string of positive developments.
Next Coronavirus Market Crash: Where to Invest $10,000 | The Motley Fool
10:55am, Saturday, 03'rd Oct 2020
Prep your portfolio by buying shares of healthcare companies that can deliver revenue growth in the worst of times.
